In the TRIDENT-1 trial, repotrectinib demonstrated an ORR ranging from 40% to 67% in ROS1-positive NSCLC patients who had received one or more prior ROS1 TKI [39]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.